Table 5.

Subgroup comparisons for the CV outcomes.

Treatment	Endpoint	Participant	RR	95% CI	P value	I2 (%)	Subgroups difference (P value)
Conventional lipid-lowering strategies (including statins and ezetimibe)	CV death	22,294/21,853	0.87	0.70–1.08	.20	71	.59
PCKS9-mAbs		14,261/13,867	0.43	0.04–5.30	.51	64
Conventional lipid-lowering strategies (including statins and ezetimibe)	MI	25,184/25,128	0.83	0.77–0.89	<.001	61	.89
PCKS9-mAbs		14,631/14,455	0.73	0.65–0.82	<.001	0
Conventional lipid-lowering strategies (including statins and ezetimibe)	Stroke	21,685/21,704	0.79	0.57–1.10	.17	59	.98
PCKS9-mAbs		14,268/14,264	0.79	0.66–0.94	.01	0

CI = confidence interval, CRP = C-reactive protein, CV = cardiovascular, MI = myocardial infarction, PCSK9-mAb = proprotein convertase subtilisin/kexin type 9 monoclonal antibody, RR = risk ratio.